Literature DB >> 26459635

Prognostic Value of Coronary Flow Reserve in Patients with Dialysis-Dependent ESRD.

Nishant R Shah1, David M Charytan2, Venkatesh L Murthy3, Hicham Skali Lami2, Vikas Veeranna4, Michael K Cheezum4, Viviany R Taqueti4, Takashi Kato5, Courtney R Foster6, Jon Hainer6, Mariya Gaber6, Josh Klein2, Sharmila Dorbala4, Ron Blankstein4, Marcelo F Di Carli4.   

Abstract

Capillary rarefaction of the coronary microcirculation is a consistent phenotype in patients with dialysis-dependent ESRD (dd-ESRD) and may help explain their excess mortality. Global coronary flow reserve (CFR) assessed by positron emission tomography (PET) is a noninvasive, quantitative marker of myocardial perfusion and ischemia that integrates the hemodynamic effects of epicardial stenosis, diffuse atherosclerosis, and microvascular dysfunction. We tested whether global CFR provides risk stratification in patients with dd-ESRD. Consecutive patients with dd-ESRD clinically referred for myocardial perfusion PET imaging were retrospectively included, excluding patients with prior renal transplantation. Per-patient CFR was calculated as the ratio of stress to rest absolute myocardial blood flow. Multivariable Cox proportional hazards models, including age, overt cardiovascular disease, and myocardial scar/ischemia burden, were used to assess the independent association of global CFR with all-cause and cardiovascular mortality. The incremental value of global CFR was assessed with relative integrated discrimination index and net reclassification improvement. In 168 patients included, median global CFR was 1.4 (interquartile range, 1.2-1.8). During follow-up (median of 3 years), 36 patients died, including 21 cardiovascular deaths. Log-transformed global CFR independently associated with all-cause mortality (hazard ratio, 0.01 per 0.5-unit increase; 95% confidence interval, <0.01 to 0.14; P<0.001) and cardiovascular mortality (hazard ratio, 0.01 per 0.5-unit increase; 95% confidence interval, <0.01 to 0.15; P=0.002). For all-cause mortality, addition of global CFR resulted in risk reclassification in 27% of patients. Thus, global CFR may provide independent and incremental risk stratification for all-cause and cardiovascular mortality in patients with dd-ESRD.
Copyright © 2016 by the American Society of Nephrology.

Entities:  

Keywords:  cardiovascular disease; mortality risk; outcomes; survival

Mesh:

Year:  2015        PMID: 26459635      PMCID: PMC4884106          DOI: 10.1681/ASN.2015030301

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  25 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

Review 2.  US Renal Data System 2013 Annual Data Report.

Authors:  Allan J Collins; Robert N Foley; Blanche Chavers; David Gilbertson; Charles Herzog; Areef Ishani; Kirsten Johansen; Bertram L Kasiske; Nancy Kutner; Jiannong Liu; Wendy St Peter; Haifeng Guo; Yan Hu; Allyson Kats; Shuling Li; Suying Li; Julia Maloney; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Bryn Thompson; Eric Weinhandl; Hui Xiong; Akeem Yusuf; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frank Daniels; James Ebben; Eric Frazier; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Delaney Berrini; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa
Journal:  Am J Kidney Dis       Date:  2014-01       Impact factor: 8.860

Review 3.  Anatomic versus physiologic assessment of coronary artery disease. Role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making.

Authors:  K Lance Gould; Nils P Johnson; Timothy M Bateman; Rob S Beanlands; Frank M Bengel; Robert Bober; Paolo G Camici; Manuel D Cerqueira; Benjamin J W Chow; Marcelo F Di Carli; Sharmila Dorbala; Henry Gewirtz; Robert J Gropler; Philipp A Kaufmann; Paul Knaapen; Juhani Knuuti; Michael E Merhige; K Peter Rentrop; Terrence D Ruddy; Heinrich R Schelbert; Thomas H Schindler; Markus Schwaiger; Stefano Sdringola; John Vitarello; Kim A Williams; Donald Gordon; Vasken Dilsizian; Jagat Narula
Journal:  J Am Coll Cardiol       Date:  2013-08-28       Impact factor: 24.094

Review 4.  Does coronary flow trump coronary anatomy?

Authors:  K Lance Gould
Journal:  JACC Cardiovasc Imaging       Date:  2009-08

5.  Hypertrophy of intramyocardial arteriolar smooth muscle cells in experimental renal failure.

Authors:  J Törnig; M L Gross; A Simonaviciene; G Mall; E Ritz; K Amann
Journal:  J Am Soc Nephrol       Date:  1999-01       Impact factor: 10.121

6.  Coronary vascular dysfunction and prognosis in patients with chronic kidney disease.

Authors:  Venkatesh L Murthy; Masanao Naya; Courtney R Foster; Jon Hainer; Mariya Gaber; Sharmila Dorbala; David M Charytan; Ron Blankstein; Marcelo F Di Carli
Journal:  JACC Cardiovasc Imaging       Date:  2012-10

7.  Volume overload left ventricular hypertrophy: effects on coronary microvascular reactivity in rabbits.

Authors:  J D Symons; S Gunawardena; C T Kappagoda; M R Dhond
Journal:  Exp Physiol       Date:  2001-11       Impact factor: 2.969

8.  Myocyte/capillary mismatch in the heart of uremic patients.

Authors:  K Amann; M Breitbach; E Ritz; G Mall
Journal:  J Am Soc Nephrol       Date:  1998-06       Impact factor: 10.121

9.  Association between LDL-C and risk of myocardial infarction in CKD.

Authors:  Marcello Tonelli; Paul Muntner; Anita Lloyd; Braden Manns; Scott Klarenbach; Neesh Pannu; Matthew James; Brenda Hemmelgarn
Journal:  J Am Soc Nephrol       Date:  2013-05-16       Impact factor: 10.121

10.  Restricted coronary flow reserve in patients with mitral regurgitation improves after mitral reconstructive surgery.

Authors:  T Akasaka; K Yoshida; T Hozumi; T Takagi; S Kaji; T Kawamoto; Y Ueda; Y Okada; S Morioka; J Yoshikawa
Journal:  J Am Coll Cardiol       Date:  1998-12       Impact factor: 24.094

View more
  24 in total

Review 1.  Quantification of PET Myocardial Blood Flow.

Authors:  Matthieu Pelletier-Galarneau; Patrick Martineau; Georges El Fakhri
Journal:  Curr Cardiol Rep       Date:  2019-02-28       Impact factor: 2.931

Review 2.  Updates on Stress Imaging Testing and Myocardial Viability With Advanced Imaging Modalities.

Authors:  Sandeep S Hedgire; Michael Osborne; Daniel J Verdini; Brian B Ghoshhajra
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-04

3.  Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney Impairment.

Authors:  Navkaranbir S Bajaj; Amitoj Singh; Wunan Zhou; Ankur Gupta; Kana Fujikura; Christina Byrne; Hendrik J Harms; Michael T Osborne; Paco Bravo; Efstathia Andrikopolou; Sanjay Divakaran; Courtney F Bibbo; Jon Hainer; Hicham Skali; Viviany Taqueti; Michael Steigner; Sharmila Dorbala; David M Charytan; Sumanth D Prabhu; Ron Blankstein; Rahul C Deo; Scott D Solomon; Marcelo F Di Carli
Journal:  Circulation       Date:  2019-11-29       Impact factor: 29.690

4.  Measurement of MBF by PET is ready for prime time as an integral part of clinical reports in diagnosis and risk assessment of patients with known or suspected CAD-PRO.

Authors:  Marcelo F Di Carli
Journal:  J Nucl Cardiol       Date:  2017-08-22       Impact factor: 5.952

5.  Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC.

Authors:  Venkatesh L Murthy; Timothy M Bateman; Rob S Beanlands; Daniel S Berman; Salvador Borges-Neto; Panithaya Chareonthaitawee; Manuel D Cerqueira; Robert A deKemp; E Gordon DePuey; Vasken Dilsizian; Sharmila Dorbala; Edward P Ficaro; Ernest V Garcia; Henry Gewirtz; Gary V Heller; Howard C Lewin; Saurabh Malhotra; April Mann; Terrence D Ruddy; Thomas H Schindler; Ronald G Schwartz; Piotr J Slomka; Prem Soman; Marcelo F Di Carli; Andrew Einstein; Raymond Russell; James R Corbett
Journal:  J Nucl Cardiol       Date:  2018-02       Impact factor: 5.952

6.  Aldosterone impairs coronary adenosine-mediated vasodilation via reduced functional expression of Ca2+-activated K+ channels.

Authors:  Maloree Khan; Alex I Meuth; Scott M Brown; Bysani Chandrasekar; Douglas K Bowles; Shawn B Bender
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-06-14       Impact factor: 4.733

Review 7.  Assessing the Haemodynamic Impact of Coronary Artery Stenoses: Intracoronary Flow Versus Pressure Measurements.

Authors:  Valérie E Stegehuis; Gilbert Wm Wijntjens; Tadashi Murai; Jan J Piek; Tim P van de Hoef
Journal:  Eur Cardiol       Date:  2018-08

Review 8.  ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on 'coronary microvascular dysfunction in cardiovascular disease'.

Authors:  Teresa Padro; Olivia Manfrini; Raffaele Bugiardini; John Canty; Edina Cenko; Giuseppe De Luca; Dirk J Duncker; Etto C Eringa; Akos Koller; Dimitris Tousoulis; Danijela Trifunovic; Marija Vavlukis; Cor de Wit; Lina Badimon
Journal:  Cardiovasc Res       Date:  2020-03-01       Impact factor: 10.787

Review 9.  Assessment of myocardial blood flow and coronary flow reserve with positron emission tomography in ischemic heart disease: current state and future directions.

Authors:  Firas Al Badarin; Ahmed Aljizeeri; Fatimah Almasoudi; Mouaz H Al-Mallah
Journal:  Heart Fail Rev       Date:  2017-07       Impact factor: 4.214

10.  Thallium-201 washout rate of stress myocardial perfusion imaging as a predictor of mortality in diabetic kidney disease patients initiating hemodialysis: an observational, follow-up study.

Authors:  Toshihide Hayashi; Nobuhiko Joki; Yuri Tanaka; Masaki Iwasaki; Shun Kubo; Ai Matsukane; Yasunori Takahashi; Yoshihiko Imamura; Koichi Hirahata; Hiroki Hase
Journal:  Clin Exp Nephrol       Date:  2017-04-21       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.